Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone

被引:33
作者
Savolainen, J
Leppanen, J
Forsberg, M
Taipale, H
Nevalainen, T
Huuskonen, J
Gynther, J
Mannisto, PT
Jarvinen, T
机构
[1] Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland
[2] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
[3] Finncovery Ltd, Kuopio 70200, Finland
基金
芬兰科学院;
关键词
entacapone; prodrug; carbamates; bioavailability; COMT inhibitor;
D O I
10.1016/S0024-3205(00)00615-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Entacapone has a relatively low oral bioavailability which may, in part, be due to its low aqueous solubility at low pH and/or its hydrophilic character at neutral pH. Various novel N-alkyl and N,N-dialkyl carbamate esters of entacapone were synthesized as possible prodrugs of entacapone in order to increase its aqueous solubility at an acidic pH and to increase its lipophilicity at neutral pH. Oral bioavailability of entacapone and selected carbamate esters were investigated in rats. Both N-alkyl and N,N-dialkyl carbamate esters were relatively stable against chemical hydrolysis at pH 7.4 (t(1/2) = 14.9-20.7 h), but hydrolyzed rapidly (t(1/2) = 0.8-2.7 h) in human serum. However, in contrast to N-alkyl carbamates, N,N-dialkyl carbamates did not release entacapone in in vitro enzymatic hydrolysis (human serum) studies. N-Alkyl carbamates, 2a-c, showed increased aqueous solubility at pH 7.4, of which 2a and 2c also show increased aqueous solubility at pH 5.0, compared to entacapone, In addition to increased aqueous solubility, 2c showed increased lipophilicity at pH 7.4. However, two N-alkyl carbamates of entacapone did not increase the oral bioavailability of the parent drug in rats. Thus, it can be concluded that the relatively low lipophilicity of entacapone is not the cause of its low bioavailability. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:205 / 216
页数:12
相关论文
共 22 条
  • [1] SYNTHESIS OF SOME NOVEL POTENT AND SELECTIVE CATECHOL O-METHYLTRANSFERASE INHIBITORS
    BACKSTROM, R
    HONKANEN, E
    PIPPURI, A
    KAIRISALO, P
    PYSTYNEN, J
    HEINOLA, K
    NISSINEN, E
    LINDEN, IB
    MANNISTO, PT
    KAAKKOLA, S
    POHTO, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (04) : 841 - 846
  • [2] THE EFFECT OF BAMBUTEROL (CARBAMYLATED TERBUTALINE) ON PLASMA CHOLINESTERASE ACTIVITY AND SUXAMETHONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN GENOTYPICALLY NORMAL-PATIENTS
    BANG, U
    VIBYMOGENSEN, J
    WIREN, JE
    SKOVGAARD, LT
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1990, 34 (07) : 596 - 599
  • [3] POTENTIAL ANTI-AIDS DRUGS - LIPOPHILIC, ADENOSINE DEAMINASE-ACTIVATED PRODRUGS
    BARCHI, JJ
    MARQUEZ, VE
    DRISCOLL, JS
    FORD, H
    MITSUYA, H
    SHIRASAKA, T
    AOKI, S
    KELLEY, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (05) : 1647 - 1655
  • [4] Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight
    Camenisch, G
    Alsenz, J
    van de Waterbeemd, H
    Folkers, G
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (04) : 313 - 319
  • [5] Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs
    Fleisher, D
    Bong, R
    Stewart, BH
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (02) : 115 - 130
  • [6] Florence A.T., 1988, PHYSICOCHEMICAL PRIN, V2nd ed.
  • [7] GULDBERG HC, 1975, PHARMACOL REV, V27, P135
  • [8] JUELFRIIS G, 1996, TXB DRUG DESIGN DEV, P351
  • [9] EFFECT OF ENTACAPONE, A COMT INHIBITOR, ON CLINICAL DISABILITY AND LEVODOPA METABOLISM IN PARKINSONIAN-PATIENTS
    KAAKKOLA, S
    TERAVAINEN, H
    AHTILA, S
    RITA, H
    GORDIN, A
    [J]. NEUROLOGY, 1994, 44 (01) : 77 - 80
  • [10] KARARLI TT, 1989, CRIT REV THER DRUG, V6, P39